In a cohort of US females, a levonorgestrel (LNG) 52-mg intrauterine system (IUS) showed high 5-year contraceptive efficacy and low hormonal adverse effect rates, according to a phase 3 study. Researchers enrolled 1,751 nulliparous and parous females aged 16‒45 years and desiring contraception to receive a novel LNG 52-mg IUS at 29 centers in the US. Participations had scheduled follow-up visits 4 times during the first year; every 6 months after year 1. The primary outcome was pregnancy rate at enrollment through 60 months. Among the findings:
- The 1,751 enrollees included 1,600 females aged 16‒35 years and 151 aged 36‒45 years.
- Successful IUS placement occurred in 1,714 (97.9%) participants.
- 495 participants finished 5 years and 176 had entered the seventh year of IUS use at the time of data evaluation.
- The cumulative life-table pregnancy rate was 0.92% through 5 years.
- Discontinuation for adverse events occurred in 322 (18.8%) participants, most commonly related to expulsion.
Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. [Published online ahead of print December 4, 2018]. Obstet Gynecol. doi:10.1097/AOG.0000000000003034.
Must Reads in Contraception
Bleeding and Spotting with the LNG 13.5 mg IUS, Contraception; ePub 2019 Mar 1; Shimoni, et al
Contraception and Chronic Opioid Prescriptions, Contraception; ePub 2019 Feb 11; Ray-Griffith, et al
Hormonal Contraception & Coexisting Medical Conditions, Obstet Gynecol; ePub 2019 Feb; Allen, et al
Contraceptive Switching & Discontinuation, Am J Obstet Gynecol; ePub 2018 Dec 18; Simmons, et al